245 related articles for article (PubMed ID: 32826305)
1. Reciprocal regulation of pancreatic ductal adenocarcinoma growth and molecular subtype by HNF4α and SIX1/4.
Camolotto SA; Belova VK; Torre-Healy L; Vahrenkamp JM; Berrett KC; Conway H; Shea J; Stubben C; Moffitt R; Gertz J; Snyder EL
Gut; 2021 May; 70(5):900-914. PubMed ID: 32826305
[TBL] [Abstract][Full Text] [Related]
2. CES2 sustains HNF4α expression to promote pancreatic adenocarcinoma progression through an epoxide hydrolase-dependent regulatory loop.
Chen Y; Capello M; Rios Perez MV; Vykoukal JV; Roife D; Kang Y; Prakash LR; Katayama H; Irajizad E; Fleury A; Ferri-Borgogno S; Baluya DL; Dennison JB; Do KA; Fiehn O; Maitra A; Wang H; Chiao PJ; Katz MHG; Fleming JB; Hanash SM; Fahrmann JF
Mol Metab; 2022 Feb; 56():101426. PubMed ID: 34971802
[TBL] [Abstract][Full Text] [Related]
3. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
5. EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of
Patil S; Steuber B; Kopp W; Kari V; Urbach L; Wang X; Küffer S; Bohnenberger H; Spyropoulou D; Zhang Z; Versemann L; Bösherz MS; Brunner M; Gaedcke J; Ströbel P; Zhang JS; Neesse A; Ellenrieder V; Singh SK; Johnsen SA; Hessmann E
Cancer Res; 2020 Nov; 80(21):4620-4632. PubMed ID: 32907838
[TBL] [Abstract][Full Text] [Related]
6. Sineoculis homeobox homolog 1 protein overexpression as an independent biomarker for pancreatic ductal adenocarcinoma.
Jin A; Xu Y; Liu S; Jin T; Li Z; Jin H; Lin L; Lin Z
Exp Mol Pathol; 2014 Feb; 96(1):54-60. PubMed ID: 24263054
[TBL] [Abstract][Full Text] [Related]
7. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
8. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma.
Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM
J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030
[TBL] [Abstract][Full Text] [Related]
9. Loss of the transcriptional repressor TGIF1 results in enhanced Kras-driven development of pancreatic cancer.
Weng CC; Hsieh MJ; Wu CC; Lin YC; Shan YS; Hung WC; Chen LT; Cheng KH
Mol Cancer; 2019 May; 18(1):96. PubMed ID: 31109321
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer.
Lerbs T; Bisht S; Schölch S; Pecqueux M; Kristiansen G; Schneider M; Hofmann BT; Welsch T; Reissfelder C; Rahbari NN; Fritzmann J; Brossart P; Weitz J; Feldmann G; Kahlert C
BMC Cancer; 2017 Apr; 17(1):249. PubMed ID: 28388884
[TBL] [Abstract][Full Text] [Related]
11. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Zhu L; Wang X
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
[TBL] [Abstract][Full Text] [Related]
12. GATA6 Expression Distinguishes Classical and Basal-like Subtypes in Advanced Pancreatic Cancer.
O'Kane GM; Grünwald BT; Jang GH; Masoomian M; Picardo S; Grant RC; Denroche RE; Zhang A; Wang Y; Lam B; Krzyzanowski PM; Lungu IM; Bartlett JMS; Peralta M; Vyas F; Khokha R; Biagi J; Chadwick D; Ramotar S; Hutchinson S; Dodd A; Wilson JM; Notta F; Zogopoulos G; Gallinger S; Knox JJ; Fischer SE
Clin Cancer Res; 2020 Sep; 26(18):4901-4910. PubMed ID: 32156747
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
14. Chromatin-Independent Interplay of NFATc1 and EZH2 in Pancreatic Cancer.
Patil S; Forster T; Reutlinger K; Kopp W; Versemann L; Spitalieri J; Gaedcke J; Ströbel P; Singh SK; Ellenrieder V; Neesse A; Hessmann E
Cells; 2021 Dec; 10(12):. PubMed ID: 34943970
[TBL] [Abstract][Full Text] [Related]
15. Overall survival of pancreatic ductal adenocarcinoma is doubled by
Lee JS; Lee H; Woo SM; Jang H; Jeon Y; Kim HY; Song J; Lee WJ; Hong EK; Park SJ; Han SS; Kim SY
Theranostics; 2021; 11(7):3472-3488. PubMed ID: 33537098
[No Abstract] [Full Text] [Related]
16. The role of lineage specifiers in pancreatic ductal adenocarcinoma.
Camolotto SA; Belova VK; Snyder EL
J Gastrointest Oncol; 2018 Dec; 9(6):1005-1013. PubMed ID: 30603119
[TBL] [Abstract][Full Text] [Related]
17. A mucus production programme promotes classical pancreatic ductal adenocarcinoma.
Tonelli C; Yordanov GN; Hao Y; Deschênes A; Hinds J; Belleau P; Klingbeil O; Brosnan E; Doshi A; Park Y; Hruban RH; Vakoc CR; Dobin A; Preall J; Tuveson DA
Gut; 2024 May; 73(6):941-954. PubMed ID: 38262672
[TBL] [Abstract][Full Text] [Related]
18. A gene expression signature of epithelial tubulogenesis and a role for ASPM in pancreatic tumor progression.
Wang WY; Hsu CC; Wang TY; Li CR; Hou YC; Chu JM; Lee CT; Liu MS; Su JJ; Jian KY; Huang SS; Jiang SS; Shan YS; Lin PW; Shen YY; Lee MT; Chan TS; Chang CC; Chen CH; Chang IS; Lee YL; Chen LT; Tsai KK
Gastroenterology; 2013 Nov; 145(5):1110-20. PubMed ID: 23896173
[TBL] [Abstract][Full Text] [Related]
19. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
[TBL] [Abstract][Full Text] [Related]
20. Expression of HOXC8 is inversely related to the progression and metastasis of pancreatic ductal adenocarcinoma.
Adwan H; Zhivkova-Galunska M; Georges R; Eyol E; Kleeff J; Giese NA; Friess H; Bergmann F; Berger MR
Br J Cancer; 2011 Jul; 105(2):288-95. PubMed ID: 21712827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
